Trial reportThe European respiratory journal2017
A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma.
Trial report in The European respiratory journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01277523 (A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler), which is not on this map. Cited by 38 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomised, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate Efficacy and Safety of Tiotropium Inhalation Solution Delivered Via Respimat® Inhaler (2.5 mcg and 5 mcg Once Daily) Over 12 Weeks as add-on Controller Therapy on Top of Usual Care in Adolescents (12 to 17 Years Old) With Severe Persistent Asthma
Who cites it
38 citing papers in PubMed, 6 syntheses or guidelines pooled it, 107 citations in OpenAlex.
- Addition of long-acting beta2 agonists or long-acting muscarinic antagonists versus doubling the dose of inhaled corticosteroids (ICS) in adolescents and adults with uncontrolled asthma with medium dose ICS: a systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying doses of inhaled corticosteroids in adolescents and adults with asthma: a systematic review and network meta-analysis.The Cochrane database of systematic reviews · 2022Pooled it
- Burden of Asthma and Role of 2.5 µg Tiotropium RespimatAdvances in therapy · 2019Pooled it
- Pooled it
- Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEVRespiratory research · 2019Pooled it
- Pooled it
- Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients.The European respiratory journal · 2019Trial
- Evaluating Severe Therapy-Resistant Asthma in Children: Diagnostic and Therapeutic Strategies.Medicina (Kaunas, Lithuania) · 2024Review
- Review
- Tiotropium as an add-on treatment to inhaled corticosteroids in children with severe and mild symptomatic asthma: Multi-center observational study for efficacy and safety analysis.Experimental and therapeutic medicine · 2022Article
- The new era of add-on asthma treatments: where do we stand?Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2022Review
- Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma.Frontiers in pediatrics · 2022Review
- 2021 Brazilian Thoracic Association recommendations for the management of severe asthma.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2021Review
- 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group.The Journal of allergy and clinical immunology · 2020Review
- Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management.NPJ primary care respiratory medicine · 2020Review
- Management of Severe Asthma Beyond the Guidelines.Current allergy and asthma reports · 2020Review
- Management of severe asthma: summary of the European Respiratory Society/American Thoracic Society task force report.Breathe (Sheffield, England) · 2020Review
- A comparison of tiotropium, long-acting βRespiratory research · 2020Review
- Future perspectives of anticholinergics for the treatment of asthma in adults and children.Therapeutics and clinical risk management · 2019Review
- Anticholinergics in asthma: are we utilizing asthma therapies effectively?Therapeutics and clinical risk management · 2019Article
Corrections and comments
- Commented on by
Authors and funding
8 authors at 6 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We present results from the first phase III trial of once-daily tiotropium add-on to inhaled corticosteroids (ICS) plus one or more controller therapies in adolescents with severe symptomatic asthma.In this double-blind, parallel-group trial (NCT01277523), 392 patients aged 12-17 years were randomised to receive once-daily tiotropium 5 µg or 2.5 µg, or placebo, as an add-on to ICS plus other controller therapies over 12 weeks. The primary and key secondary end-points were change from baseline (response) in peak forced expiratory volume in 1 s (FEV
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.